These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
159 related articles for article (PubMed ID: 2968349)
1. Prevention of urinary albumin excretion in 6 month streptozocin-diabetic rats with the aldose reductase inhibitor tolrestat. McCaleb ML; Sredy J; Millen J; Ackerman DM; Dvornik D J Diabet Complications; 1988; 2(1):16-8. PubMed ID: 2968349 [TBL] [Abstract][Full Text] [Related]
2. Prevention of neural myoinositol depletion in diabetic rats by aldose reductase inhibition with tolrestat. Kemper C; Dvornik D Proc Soc Exp Biol Med; 1986 Sep; 182(4):505-10. PubMed ID: 3090558 [TBL] [Abstract][Full Text] [Related]
3. Intervention with the aldose reductase inhibitor, tolrestat, in renal and retinal lesions of streptozotocin-diabetic rats. McCaleb ML; McKean ML; Hohman TC; Laver N; Robison WG Diabetologia; 1991 Oct; 34(10):695-701. PubMed ID: 1959701 [TBL] [Abstract][Full Text] [Related]
4. Prevention of hemodynamic and vascular albumin filtration changes in diabetic rats by aldose reductase inhibitors. Tilton RG; Chang K; Pugliese G; Eades DM; Province MA; Sherman WR; Kilo C; Williamson JR Diabetes; 1989 Oct; 38(10):1258-70. PubMed ID: 2507378 [TBL] [Abstract][Full Text] [Related]
5. The effects of a new aldose reductase inhibitor (tolrestat) in galactosemic and diabetic rats. Simard-Duquesne N; Greselin E; Dubuc J; Dvornik D Metabolism; 1985 Oct; 34(10):885-92. PubMed ID: 3930915 [TBL] [Abstract][Full Text] [Related]
6. Correction of nerve conduction and endoneurial blood flow deficits by the aldose reductase inhibitor, tolrestat, in diabetic rats. Cotter MA; Cameron NE; Hohman TC J Peripher Nerv Syst; 1998; 3(3):217-23. PubMed ID: 10959252 [TBL] [Abstract][Full Text] [Related]
9. Effect of aldose reductase inhibitor (tolrestat) on urinary albumin excretion rate and glomerular filtration rate in IDDM subjects with nephropathy. Passariello N; Sepe J; Marrazzo G; De Cicco A; Peluso A; Pisano MC; Sgambato S; Tesauro P; D'Onofrio F Diabetes Care; 1993 May; 16(5):789-95. PubMed ID: 8495620 [TBL] [Abstract][Full Text] [Related]
10. Prolonged fructose feeding and aldose reductase inhibition: effect on the polyol pathway in kidneys of normal rats. Bellomo G; Comstock JP; Wen D; Hazelwood RL Proc Soc Exp Biol Med; 1987 Dec; 186(3):348-54. PubMed ID: 3122222 [TBL] [Abstract][Full Text] [Related]
11. Prevention of early glomerulopathy with tolrestat in the streptozotocin-induced diabetic rat. Donnelly SM; Zhou XP; Huang JT; Whiteside CI Biochem Cell Biol; 1996; 74(3):355-62. PubMed ID: 8883841 [TBL] [Abstract][Full Text] [Related]
12. Prevention of basement membrane thickening in retinal capillaries by a novel inhibitor of aldose reductase, tolrestat. Robison WG; Kador PF; Akagi Y; Kinoshita JH; Gonzalez R; Dvornik D Diabetes; 1986 Mar; 35(3):295-9. PubMed ID: 3081393 [TBL] [Abstract][Full Text] [Related]
13. Increased vascular permeability in spontaneously diabetic BB/W rats and in rats with mild versus severe streptozocin-induced diabetes. Prevention by aldose reductase inhibitors and castration. Williamson JR; Chang K; Tilton RG; Prater C; Jeffrey JR; Weigel C; Sherman WR; Eades DM; Kilo C Diabetes; 1987 Jul; 36(7):813-21. PubMed ID: 3108058 [TBL] [Abstract][Full Text] [Related]
14. N-[5-(trifluoromethyl)-6-methoxy-1-naphthalenyl]thioxomethyl]- N-methylglycine (Tolrestat), a potent, orally active aldose reductase inhibitor. Sestanj K; Bellini F; Fung S; Abraham N; Treasurywala A; Humber L; Simard-Duquesne N; Dvornik D J Med Chem; 1984 Mar; 27(3):255-6. PubMed ID: 6422042 [No Abstract] [Full Text] [Related]
15. Diabetic-like retinopathy in rats prevented with an aldose reductase inhibitor. Robison WG; Nagata M; Laver N; Hohman TC; Kinoshita JH Invest Ophthalmol Vis Sci; 1989 Nov; 30(11):2285-92. PubMed ID: 2509395 [TBL] [Abstract][Full Text] [Related]
16. Relative importance of aldose reductase versus nonenzymatic glycosylation on sugar cataract formation in diabetic rats. Kador PF; Lee JW; Fujisawa S; Blessing K; Lou MF J Ocul Pharmacol Ther; 2000 Apr; 16(2):149-60. PubMed ID: 10803425 [TBL] [Abstract][Full Text] [Related]
17. Galactose feeding causes glomerular hyperperfusion: prevention by aldose reductase inhibition. Bank N; Coco M; Aynedjian HS Am J Physiol; 1989 Jun; 256(6 Pt 2):F994-9. PubMed ID: 2500030 [TBL] [Abstract][Full Text] [Related]
18. Sorbitol metabolism in the retina, optic nerve, and sural nerve of diabetic rats treated with an aldose reductase inhibitor. Naeser P; Brolin SE; Eriksson UJ Metabolism; 1988 Dec; 37(12):1143-5. PubMed ID: 3143049 [TBL] [Abstract][Full Text] [Related]
19. Polyol pathway activity in nervous tissues of diabetic and galactose-fed rats: effect of dietary galactose withdrawal or tolrestat intervention therapy. Sredy J; Sawicki DR; Notvest RR J Diabet Complications; 1991; 5(1):42-7. PubMed ID: 1830318 [TBL] [Abstract][Full Text] [Related]
20. Sorbinil suppresses glomerular prostaglandin production in the streptozotocin diabetic rat. Craven PA; DeRubertis FR Metabolism; 1989 Jul; 38(7):649-54. PubMed ID: 2500578 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]